Year 2018 / Volume 110 / Number 10
Original
Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment

641-649

DOI: 10.17235/reed.2018.5665/2018

Albert Parés, Agustín Albillos, Raul Jesús Andrade, Marina Berenguer, Javier Crespo, Manuel Romero-Gómez, Mercè Vergara, Belén Vendrell, Alicia Gil,

Abstract
Introduction: primary biliary cholangitis (PBC) is a rare disease with limited data regarding its epidemiology and standard clinical management in Spain. Objective: to gain insight into the epidemiology, patient flow, diagnosis, follow-up and treatment of PBC in Spain. Methods: a review of the literature and Delphi study involving 28 specialists in two rounds of consultations and an in-person results validation workshop. Results: there are approximately 9,400 patients with PBC in Spain, with an annual incidence of 0.51-3.86 cases/100,000 population. Albeit, a high error margin may be presumed due to the scarcity of relevant studies on this subject. Several months may elapse from suspicion to a confirmed diagnosis, usually by a gastroenterologist or hepatologist. The role of the liver biopsy for diagnosis and follow-up is heterogeneous. Overall, 95% of patients are treated with ursodeoxycholic acid (UDCA) and response is primarily monitored using the Barcelona criteria. Follow-up is performed every six months, with a heterogeneous use of the various available techniques. No recommendations or second-line commercial drugs are available in the case of no response, inadequate response or intolerance to UDCA. Conclusions: while epidemiology may be estimated based on expert opinions, national registries are needed to provide accurate, up-to-date information on epidemiological parameters, disease stage and response to treatment in patients with PBC. Furthermore, novel therapies are required for selected patient groups.
Share Button
New comment
Comments
No comments for this article
References
1. Bowlus CL, Gershwin ME. The diagnosis of primary biliary cirrhosis. Autoimmun Rev . NIH Public Access; 2014;13(4–5):441–4.
2. Parés A. Treatment of primary biliary cirrhosis: Is there more to offer than ursodeoxycholic acid? Clin Liver Dis; 2014;3(2):29–33.
3. Nguyen DL, Juran BD, Lazaridis KN. Primary biliary cirrhosis. Best Pract Res Clin Gastroenterol. 2010;24(5):647–54.
4. Corpechot C, Chrétien Y, Chazouillères O, et.al. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol. 2010;53(1):162–9.
5. Orphanet Report Series. Prevalencia de las enfermedades raras : Datos bibliográficos Enfermedades listadas por orden de prevalencia o incidencia decreciente o por número de casos publicados [Internet]. [cited 2016 Dec 12]. Available from: http://www.orpha.net/orphacom/cahiers/docs/ES/Prevalencia_de_las_enfermedades_raras_por_prevalencia_decreciente_o_casos.pdf
6. Juran BD, Lazaridis KN. Environmental factors in primary biliary cirrhosis. Semin Liver Dis. NIH Public Access; 2014;34(3):265–72.
7. Kumagi T, Heathcote EJ. Primary biliary cirrhosis. Orphanet J Rare Dis. 2008 ;3(1):1.
8. Kurtovic J, Riordan SM, Williams R. The natural history of asymptomatic primary biliary cirrhosis. QJM An Int J Med. Oxford University Press; 2005;98(5):331–6. A
9. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009 ;50(1):291–308.
10. Al-Harthy N, Kumagi T. Natural history and management of primary biliary cirrhosis. Hepat Med. Dove Press; 2012;4:61–71.
11. Leuschner U, Manns M-P, Eisebitt R. Ursodeoxycholic Acid in the Therapy for Primary Biliary Cirrhosis: Effects on Progression and Prognosis. Z Gastroenterol. 2005;43(9):1051–9.
12. Metcalf J V, Mitchison HC, Palmer JM, et.al. Natural history of early primary biliary cirrhosis. Lancet. 1996;348(9039):1399–402.
13. Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48(3):871–7.
14. Lammers WJ, van Buuren HR, Hirschfield GM, et.al. Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. Gastroenterology. 2014;147(6):1338–1349.e5.
15. Poupon RE, Lindor KD, Cauch-Dudek K, et.al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology. 1997 Sep;113(3):884–90.
16. Corpechot C, Carrat F, Bahr A, et.al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology. 2005;128(2):297–303.
17. Angulo P, Lindor KD, Therneau TM, et.al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver. 1999;19(2):115–21.
18. Carbone M, Mells GF, Pells G, et.al. Sex and Age Are Determinants of the Clinical Phenotype of Primary Biliary Cirrhosis and Response to Ursodeoxycholic Acid. Gastroenterology. 2013;144(3):560–569.e7.
19. Kumagi T, Guindi M, Fischer SE, et.al. Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis. Am J Gastroenterol. 2010;105(10):2186–94.
20. Momah N, Silveira MG, Jorgensen R, et.al. Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. Liver Int. 2012;32(5):790–5.
21. Parés A, Caballería L, Rodés J. Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic Acid. Gastroenterology. 2006;130(3):715–20.
22. Galiè N, Humbert M, Vachiery J-L, et.al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016 Jan;37(1):67–119.
23. Kashyap R, Safadjou S, Chen R, et.al. Living Donor and Deceased Donor Liver Transplantation for Autoimmune and Cholestatic Liver Diseases—An Analysis of the UNOS Database. J Gastrointest Surg. 2010;14(9):1362–9.
24. Nevens F, Andreone P, Mazzella G, et.al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med. Massachusetts Medical Society; 2016;375(7):631–43.
25. Akamatsu N, Sugawara Y. Primary biliary cirrhosis and liver transplantation. Intractable rare Dis Res. International Advancement Center for Medicine & Health Research Co.; 2012;1(2):66–80.
26. Huang Y-Q. Recent advances in the diagnosis and treatment of primary biliary cholangitis. World J Hepatol. Baishideng Publishing Group Inc; 2016;8(33):1419–41.
27. Chalifoux SL, Konyn PG, Choi G, et.al. Extrahepatic Manifestations of Primary Biliary Cholangitis. Gut Liver. Editorial Office of Gut and Liver; 2017;11(6):771–80.
28. EMA (European Medicines Agency). Summary of Product Characteristics. Ocaliva. 2016 [cited 2017 Nov 12];1–26. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004093/WC500218418.pdf
29. Ramalle-Gómara E, Ruiz E, Quiñones C, et.al. General knowledge and opinion of future health care and non-health care professionals on rare diseases. J Eval Clin Pract. 2015;21(2):198–201.
30. Pla X, Vergara M, Gil M, et.al. Incidence, prevalence and clinical course of primary biliary cirrhosis in a Spanish community. Eur J Gastroenterol Hepatol. 2007;19(10):859–64.
31. Registro Nacional de Enfermedades colestásicas y autoinmunes hepáticas (ColHai) | AEEH [Internet]. [cited 2017 Nov 28]. Available from: http://aeeh.es/2016/11/registro-nacional-de-enfermedades-colestasicas-y-autoinmunes-hepaticas-colhai/
32. Caballero Plasencia AM, López Callejas C, Valenzuela Barranco M, et.al. [Epidemiology of primary biliary cirrhosis in the South area of Granada]. Med Clin (Barc). 1991;96(13):481–5.
33. Moreno Sánchez D, Cassinello Ogea C, González Blanco P, et.al. [Epidemiology of primary biliary cirrhosis in southern Madrid]. Med Clin (Barc). 1990;94(15):564–9.
34. Borda F, Huarte MP, Zozaya JM, et.al. [Primary biliary cirrhosis in Navarra]. An Med Interna. 1989;6(2):63–6.
35. Parés A, Bruguera M, Rodés J, et.al. [Epidemiology of primary biliary cirrhosis in Cataluna]. Med Clin (Barc). 1984;82(6):237–41.
36. Rodrigo Sáez L, Valerdiz Casasola CS, Rodríguez García M, et.al. [Epidemiology of primary biliary cirrhosis in Asturias]. Med Clin (Barc). 1987;88(12):486–9.
37. de Villiers MR, de Villiers PJT, Kent AP. The Delphi technique in health sciences education research. Med Teach. 2005;27(7):639–43.
38. Albi España Asociación para la lucha contra las enfermedades biliares inflamatorias [Internet]. [cited 2017 Nov 28]. Available from: http://www.albi-espana.org/
39. AEEH | Asociación Española para el Estudio del Hígado [Internet]. [cited 2017 Nov 28]. Available from: http://aeeh.es/
40. Orphanet. Orphan Drugs in Europe [Internet]. [cited 2017 Feb 3]. Available from: http://www.orpha.net/consor4.01/www/cgi-bin/Education_AboutOrphanDrugs.php?lng=EN&stapage=ST_EDUCATION_EDUCATION_ABOUTORPHANDRUGS_EUR
41. INE. Instituto Nacional de Estadística [Internet]. [cited 2017 Jun 13]. Available from: http://www.ine.es/
42. Boonstra K, Kunst AE, Stadhouders PH, et.al. Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study. Liver Int. 2014;34(6):e31–8.
43. Podda M, Selmi C, Lleo A, et.al. The limitations and hidden gems of the epidemiology of primary biliary cirrhosis. J Autoimmun. 2013;46:81–7.
44. Rautiainen H, Salomaa V, Niemelä S, et.al. Prevalence and incidence of primary biliary cirrhosis are increasing in Finland. Scand J Gastroenterol. 2007;42(11):1347–53.
45. Wang L, Gershwin ME, Wang F-S. Primary biliary cholangitis in China. Curr Opin Gastroenterol. 2016;32(3):1. A
46. Myers RP, Shaheen AAM, Fong A, et.al. Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: A population-based study. Hepatology. 2009;50(6):1884–92.
47. Jones DEJ, Sutcliffe K, Pairman J, et.al. An integrated care pathway improves quality of life in Primary Biliary Cirrhosis. QJM. 2008;101(7):535–43.
48. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J Hepatol. 2009;51(2):237–67.
49. Comisión Interministerial de Precios de los Medicamentos. Nota informativa de la reunión de la comisión interministerial de precios de los medicamentos. Sesión 177 de 6 de noviembre de 2017. 2017 [cited 2018 Mar 20]; Available from: https://www.msssi.gob.es/profesionales/farmacia/pdf/ACUERDOS_DE_LA_CIPM_177_web.pdf
50. AEMPS. Ficha técnica Ocaliva 5 mg comprimidos recubiertos con película [Internet]. [cited 2018 Mar 15]. Available from: https://cima.aemps.es/cima/dochtml/ft/1161139001/FT_1161139001.html
Related articles

Letter

Calcifying fibrous tumor and pathological analysis

DOI: 10.17235/reed.2023.9739/2023

Letter

Endoscopic observation of a rare duodenal tumor

DOI: 10.17235/reed.2023.9679/2023

Editorial

Recent advances in the diagnosis and management of Wilson’s disease

DOI: 10.17235/reed.2023.9633/2023

Letter

Hepatosplenic T-cell lymphoma and inflammatory bowel disease

DOI: 10.17235/reed.2023.9472/2023

Letter

New technique for the endoscopic removal of long foreign bodies

DOI: 10.17235/reed.2023.9398/2022

Letter

Vaginal lesion as first manifestation of colorectal disease

DOI: 10.17235/reed.2022.9270/2022

Letter

An uncommon colonic polyp

DOI: 10.17235/reed.2022.9160/2022

Digestive Diseases Image

An unusual cause of a protuberant lesion of the gastric antrum

DOI: 10.17235/reed.2022.8771/2022

Letter

Sigmoid colon Schwannoma simulating colon cancer

DOI: 10.17235/reed.2022.8684/2022

Editorial

Cases of liver disease lost in the health system: a call to action

DOI: 10.17235/reed.2021.8316/2021

Digestive Diseases Image

Abdominal cocoon sign: an unusual cause of intestinal obstruction

DOI: 10.17235/reed.2021.8057/2021

Letter

POEMS syndrome: an uncommon cause of peritoneal effusion

DOI: 10.17235/reed.2021.8027/2021

Digestive Diseases Image

Phlebosclerotic colitis: an unusual cause of abdominal pain and hematochezia

DOI: 10.17235/reed.2020.7358/2020

Review

New non-invasive biomarkers for colorectal cancer screening

DOI: 10.17235/reed.2020.7233/2020

Editorial

Reflex testing. A key tool for the elimination of hepatitis C

DOI: 10.17235/reed.2020.7201/2020

Letter

Chilaiditi’s and Ogilvie syndromes

DOI: 10.17235/reed.2020.7036/2020

Letter

Hepatocarcinoma diagnosis. Reflection is required

DOI: 10.17235/reed.2020.6845/2019

Letter to the Editor

Sternal cutaneous metastasis of hilar cholangiocarcinoma

DOI: 10.17235/reed.2017.4979/2017

Original

Neurogenic ppendicopathy. A report of 8 cases

DOI: 10.17235/reed.2017.4520/2016

Letter to the Editor

About human taeniasis and Taenia saginata diagnosis by endoscopy

DOI: 10.17235/reed.2016.4297/2016

Case Report

The clinical extremes of autoimmune cholangitis

DOI: 10.17235/reed.2017.4167/2015

Case Report

Primary esophageal melanoma: report of a case

DOI: 10.17235/reed.2016.3908/2015

Letter to the Editor

Unusual course of epiploic appendicitis

DOI: 10.17235/reed.2015.3796/2015

Citation tools
Parés A, Albillos A, Andrade R, Berenguer M, Crespo J, Romero-Gómez M, et all. Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment. 5665/2018


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 771 visits.
This article has been downloaded 605 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 20/04/2018

Accepted: 08/05/2018

Online First: 23/07/2018

Published: 01/10/2018

Article revision time: 3 days

Article Online First time: 94 days

Article editing time: 164 days


Share
This article has been rated by 3 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology